Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 3Colitis 2Urogenital Neoplasms 1Skin Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Colitis, Ulcerative 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 7cemiplimab 6Nivolumab 5avelumab 3encorafenib 2binimetinib 2Radiotherapy 2Ipilimumab 2Immune Checkpoint Inhibitors 2Blood Specimen Collection 2toripalimab 1tislelizumab 1lifileucel 1lenvatinib 1durvalumab 1dostarlimab 1cobimetinib 1atezolizumab 1Vemurafenib 1Surveys and Questionnaires 1Sirolimus 1Radiosurgery 1Prednisone 1Paclitaxel 1Oxaliplatin 1Observation 1Mohs Surgery 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Skin Neoplasms × Infliximab × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡